Abstract:

In modern aging society, the incidence of Alzheimer’s disease(AD) has been increasing significantly. However, the pathogenesis of AD has not ever been elucidated, and effective treatment for AD is unavailable. Recent study reported that the risk for AD has a high correlation with Type Ⅱ diabetes. There is now an extensive evidence that has demonstrated the efficacy of peroxisome proliferator-activated receptor gamma(PPARγ) agonists rosiglitazone in ameliorating disease-related pathology and improved learning and memory in AD patients and animal models. These evidences and the mechanism of rosiglitazone are reviewed in this paper.

Key words: peroxisome proliferator-activated receptor gamma, rosiglitazone, Alzheimer&rsquo, s disease, amyloid beta, inflammation, apolipoprotein E